Lineage Cell Therapeutics, Inc.
LCTX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000876343
No open-market purchases or sales by Lineage Cell Therapeutics, Inc. insiders were filed in the last 90 days; 131 institutions reported holding it in 13F filings for Q2 2026, worth $152.7M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Lineage Cell Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 107 | 104 | −3 |
| Shares | 75.6M | 75.5M | −133.4K (−0.2%) |
| Value | $106.6M | $89.1M | −$17.5M (−16.4%) |
New holders (6)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| CIBC World Markets Inc. | 46,050 | $54.0K | 0.00% |
| Rathbone Brothers plc | 35,000 | $41.3K | 0.00% |
| Allegheny Financial Group LTD | 20,000 | $23.6K | 0.01% |
| SG Americas Securities, LLC | 19,110 | $23.0K | 0.00% |
| AE Wealth Management LLC | 15,543 | $18.3K | 0.00% |
| Comerica Bank | 295 | $348 | 0.00% |
Sold out (9)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| HRT Financial LP | 744,628 | $1.05M |
| DAFNA Capital Management LLC | 140,000 | $197.4K |
| Two Sigma Investments, LP | 81,816 | $115.4K |
| Verition Fund Management LLC | 42,304 | $59.6K |
| Susquehanna International Group, LLP | 41,181 | $58.1K |
| Gsa Capital Partners LLP | 13,196 | $19.0K |
| Archer Investment Corp | 1,000 | $1.41K |
| Group One Trading, L.P. | 972 | $1.37K |
| Stonebridge Capital Advisors LLC | 29 | $41 |